Mydayis

Mydayis is an extended-release central nervous system (CNS) stimulant formulation containing mixed salts of a single-entity amphetamine product (amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate). It contains d-amphetamine and l-amphetamine salts in a 3:1 ratio. Developed by Shire (now Takeda) and approved by the FDA in 2017, Mydayis is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 13 years and older. The drug utilizes a unique triple-bead delivery system—comprising one immediate-release and two delayed-release beads—that provides a duration of action up to 16 hours, intended for once-daily morning administration. Its mechanism of action involves increasing synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake via the dopamine transporter (DAT) and norepinephrine transporter (NET), as well as promoting their release from presynaptic stores through interactions with VMAT2 and TAAR1. Due to its high potential for abuse and dependence, it is classified as a Schedule II controlled substance.

Brand names

Mydayis

Other names

triple-bead mixed amphetamine saltsmixed amphetamine salts